Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on all four occasions. Overall, Alexion has posted an average positive earnings surprise of 11.91% for the trailing four quarters.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the fourth quarter of 2017. Our consensus called for EPS of $1.09, and the company reported EPS of $1.48.
Revenue: Revenues, also, beat expectations. Alexion posted revenues of $909.7 million, compared to our consensus estimate of $878 million.
Key Stats:Soliris sales increased 5.8% in the quarter to $791.9 million. During the quarter the company received approval for expanded indication of Soliris in the United States, Europe and Japan for the treatment of refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor antibody-positive.
2018 Guidance: The company provided guidance for 2018. The company expects earnings per share to be in the range of $6.60 to $6.80. It projects revenues to be in the range of $3.85 to $3.95 billion. The Zacks Consensus Estimate for earnings for 2018 was $7.07 per share while for sales it was $4.06 billion.
Share Price Impact:There was no movement in pre-market trading.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think.
See This Ticker Free >>
Image: Bigstock
Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates
Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on all four occasions. Overall, Alexion has posted an average positive earnings surprise of 11.91% for the trailing four quarters.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the fourth quarter of 2017. Our consensus called for EPS of $1.09, and the company reported EPS of $1.48.
Revenue: Revenues, also, beat expectations. Alexion posted revenues of $909.7 million, compared to our consensus estimate of $878 million.
Key Stats:Soliris sales increased 5.8% in the quarter to $791.9 million. During the quarter the company received approval for expanded indication of Soliris in the United States, Europe and Japan for the treatment of refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor antibody-positive.
2018 Guidance: The company provided guidance for 2018. The company expects earnings per share to be in the range of $6.60 to $6.80. It projects revenues to be in the range of $3.85 to $3.95 billion. The Zacks Consensus Estimate for earnings for 2018 was $7.07 per share while for sales it was $4.06 billion.
Share Price Impact:There was no movement in pre-market trading.
Alexion Pharmaceuticals, Inc. Price and Consensus
Alexion Pharmaceuticals, Inc. Price and Consensus | Alexion Pharmaceuticals, Inc. Quote
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think.
See This Ticker Free >>